Learn how immunotherapies harness a person’s immune system to fight diseases
Learn more about Aduro’s clinical programs
Download the 2018 Annual Report
November 08, 2019 Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual Meeting
Are you interested in working for a company where interactions are authentic, commitment is high and people excel together?